Similar articles

• [New bone density conservation agents for osteoporosis under research and development: Ibandronate].

  Tanaka I, Hashimoto J, Oshima H. Tanaka I, et al. Nihon Rinsho. 2007 Nov 28;65 Suppl 9:426-32. Nihon Rinsho. 2007. PMID: 18161144 Review. Japanese. No abstract available.
• [Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis].

  Tanaka M, Mori H, Shimizu K, Toshiyuki, Matsuoka, Yamamotoya H, Minamide T, Mori M, Nozaki K, Usui T, Shimokawa K, Suzuki H, Aoyama K, Kimoto A, Sasamata M, Miyata K. Tanaka M, et al. Nihon Yakurigaku Zasshi. 2009 Sep;134(3):149-57. doi: 10.1254/fpj.134.149. Nihon Yakurigaku Zasshi. 2009. PMID: 19749488 Review. Japanese. No abstract available.
• [Ibandronate].

  Tobinai M. Tobinai M. Clin Calcium. 2011 Jan;21(1):79-86. Clin Calcium. 2011. PMID: 21187598 Review. Japanese.
• Intravenous ibandronate or sodium-fluoride--a 3.5 years study on bone density and fractures in Crohn's disease patients with osteoporosis.

  Klaus J, Reinshagen M, Herdt K, Adler G, von Boyen GB, von Tirpitz C. Klaus J, et al. J Gastrointestin Liver Dis. 2011 Jun;20(2):141-8. J Gastrointestin Liver Dis. 2011. PMID: 21725510 Clinical Trial.
• Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?

  Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Black DM, et al. N Engl J Med. 2012 May 31;366(22):2051-3. doi: 10.1056/NEJMp1202623. Epub 2012 May 9. N Engl J Med. 2012. PMID: 22571169 Free PMC article. No abstract available.